| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000009821 |
| Receipt No. | R000011412 |
| Scientific Title | Airway biomarkers and air pollution in patients with asthma and other airway diseases |
| Date of disclosure of the study information | 2013/01/22 |
| Last modified on | 2020/01/16 (Ver. 5) |
| Basic information | ||
| Public title | Airway biomarkers and air pollution in patients with asthma and other airway diseases | |
| Acronym | Airway biomarkers and pollution | |
| Scientific Title | Airway biomarkers and air pollution in patients with asthma and other airway diseases | |
| Scientific Title:Acronym | Airway biomarkers and pollution | |
| Region |
|
|
| Condition | ||
| Condition | bronchial asthma and other respiratoroy diseaseas, sharing some clinical manifestation. | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | We so far demonstrated that Nrf-1, or a transcription factor regulating expression of anti-oxidant-associated genes, is a good biomarker for airway inflammation, and that it is associated with environmental pollution. The aim of this study is to clarify how these baiomarkers, polymorphism of anti-oxidant genes, and environmental pollution are associated with pathogenesis of asthma and other airway disaeses. |
| Basic objectives2 | Others |
| Basic objectives -Others | Effect of air pollution on the airway is to be evaluated: biomarkers for cytokines, growth factors, and oxidative stress in exhaled breath condensates and blood, are measured. In addtion, polymorphisms of genes responding to oxidative stress are determined. It is also defined how much environmental air is polluted in participants' residential area. General and clinical indicators of asthma and its control are also evaluated. By assessing these biomarkers and data togeter, the study aims at description of how environmental air affect the airway inflammation, and of which is associated with development of asthma or other diseases. |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | (1) Air pollution
(2) general assessment of asthma and airway inflammation (3) genetic polymorphism Association between them is investigated. |
| Key secondary outcomes | In addition to the above mentioned intems, the following items is investigated, indcluidng
(1) mediators in EBC (2) mediators in blood (3) oxidative stress of EBC and blood (4) inflammatory biomarkers |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Participants are those who were already diagnosed or suspected with asthma, those who chronically complain respiratory symptoms such as cough, those who were allergic with no symptoms, and those who might be other diseases with respiratopry symptoms including COPD, lung cancer and disseminated lung diseases, as well as healthy individuals. In this process, internationa primary care airway group (IPAG) quesstionairres and other questionnairres will be utilized. They should be twenty years old or over and give informed consent on the basis that the study is approved by each local ethics committee.
|
|||
| Key exclusion criteria | Those whe are dianosed with pulmonary infection, severe cardiologic, hepatic and/or renal issues, are to be excluded. This decision is to be made according by physicians in charge.
|
|||
| Target sample size | 280 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kyorin University School of Medicine | ||||||
| Division name | Department of Respiratyry Medicine | ||||||
| Zip code | 181-8611 | ||||||
| Address | 6-20-2 Shinkawa, Mitaka, Tokyo | ||||||
| TEL | 0422-47-5511 | ||||||
| htakizawa-alg@umin.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kyorin University | ||||||
| Division name | Ethical Committee | ||||||
| Zip code | 181-8611 | ||||||
| Address | 6-20-2 Shinkawa, Mitaka, Tokyo | ||||||
| TEL | 0422-47-5511 | ||||||
| Homepage URL | |||||||
| irb@ks.kyorin-u.ac.jp | |||||||
| Sponsor | |
| Institute | Kyorin University Shool of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Environmental Restoration and Conservation Agency |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Kyorin University |
| Address | 6-20-2,Shinkawa,Mitaka-shi,Tokyo 181-8611 JAPAN |
| Tel | 0422-47-5511 |
| irb@ks.kyorin-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 106 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | This study is cross-sectional prospective observational one, which is intended to clarify how air pollution induces airway inflammation, and, what is more, how genetic polymorphism modifies it. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000011412 |